Table 8.
Exitus in COVID-19 positive patients: univariate analysis (in-hospital stay).
| Patients, n | Exitus (n = 69) |
No Exitus (n = 317) |
p |
|---|---|---|---|
| Medical therapy during hospital stay: | |||
| Antibiotics, n | 64/69 (92.7%) | 255/317 (80.4%) | 0.01 |
| Diuretics, n | 37/69 (53.6%) | 96/317 (30.3%) | 0.001 |
| FANS, n | 17/69 (24.6%) | 70/318 (22%) | NS |
| Glucocorticoids, n | 26/69 (37.7%) | 133/316 (42%) | NS |
| Heparin, n | 54/69 (78.3%) | 272/317 (85.8%) | NS |
| Hydroxychloroquine, n | 57/69 (82.6%) | 285/316 (90.2%) | NS |
| ACEIs/ARBs, n | 23/69 (33.3%) | 117/317 (36.9%) | NS |
| Antivirals, n | 22/69 (31.9%) | 125/317 (39.4%) | NS |
| Contrast medium, n | 7/69 (10.1%) | 65/318 (20.4%) | NS |
| Clinical parameters during hospital stay: | |||
| MOF, n | 3/69 (4.3%) | 7/318 (2.2%) | NS |
| Sepsis, n | 14/69 (20.3%) | 53/318 (16.7%) | NS |
| COVID-19 related pneumonia, n | 68/69 (98.5%) | 304/318 (95.6%) | NS |
| HD, n | 0 | 6/318 (1.9%) | NS |
| Severe COVID-19, n | 49/51 (96%) | 186/213 (87.3%) | 0.04 |
| Biochemistries during hospital stay: | |||
| Serum creatinine, mg/dL | 1.36 ± 0.88 | 0.9 ± 0.34 | 0.0001 |
| Azotemia, mg/dL | 84.09 ± 45.7 | 37.7 ± 30.4 | 0.0001 |
| D-dimer, mcg/mL | 6086.5 ± 10,709.0 | 1180.8 ± 1254.8 | 0.0001 |
| IL-6, pg/mL | 51.4 ± 65.1 | 38.2 ± 168.8 | NS |
| ALT, IU/L | 45.9 ± 51.3 | 52.2 ± 42.4 | NS |
| LDH, IU/L | 418.4 ± 179.8 | 206.2 ± 69.6 | 0.001 |
| PCR, mg/dL | 52.7 ± 317.2 | 1.26 ± 2.32 | 0.004 |
| White blood cells | 10,021.7 ± 5082.5 | 6736.7 ± 2364.6 | 0.0001 |